Economic burden of female genital mutilation in 27 high-prevalence countries

David Tordrup, Chrissy Bishop, Nathan Green, Max Petzold, Fernando Ruiz Vallejo, Joshua P Vogel, Christina Pallitto

ABSTRACT

Background Female genital mutilation (FGM) is a traditional harmful practice affecting 200 million women and girls globally. Health complications of FGM occur immediately and over time, and are associated with healthcare costs that are poorly understood. Quantifying the global FGM-related burden is essential for supporting programmes and policies for prevention and mitigation.

Methods Health complications of FGM are derived from a meta-analysis and stratified by acute, uro-gynaecological, obstetric and psychological/sexual. Treatment costs are calculated from national cohort models of 27 high-burden countries over 30 years. Savings associated with full/partial abandonment are compared with a current incidence reference scenario, assuming no changes in FGM practices.

Results Our model projects an increasing burden of FGM due to population growth. As a reference scenario assuming no change in practices, prevalent cases in 27 countries will rise from 119.4 million (2018) to 205.8 million (2047). Full abandonment could reduce this to 80.0 million (2047), while partial abandonment is insufficient to reduce cases. Current incidence economic burden is US$1.4 billion/year, rising to US$2.1 billion/year in 2047. Full abandonment would reduce the future burden to US$0.8 billion/year by 2047.

Conclusion FGM is a human rights violation, a public health issue and a substantial economic burden that can be avoided through effective prevention strategies. While decreasing trends are observed in some countries, these trends are variable and not consistently observed across settings. Additional resources are needed to prevent FGM to avoid human suffering and growing costs. The findings of this study warrant increased political commitment and investment in the abandonment of FGM.

WHAT IS ALREADY KNOWN?

⇒ Abandonment of female genital mutilation is an international priority as articulated in the Sustainable Development Goals (target 5.3). In addition to being a violation of human rights and an extreme form of gender discrimination, it also carries high economic costs.

WHAT ARE THE NEW FINDINGS?

⇒ FGM is associated with increased risks of health complications that can span the life course and cost health systems an estimated 1.4 billion USD per year if reductions in the practice are not achieved.

WHAT DO THE NEW FINDINGS IMPLY?

⇒ Investment in prevention of FGM can substantially reduce the health care costs of treating its complications, prevent suffering and improve the quality of life of women and girls at-risk of this harmful practice.

The effects of FGM are physically and emotionally harmful to women and girls, accruing substantial costs to the health system. The immediate health risks of FGM include haemorrhage, shock, extreme pain, genital swelling, infections, urinary complications and problems with wound healing. Longer term consequences to women’s health and well-being can include obstetric and gynaecological complications, sexual dysfunction and psychological harm. WHO has developed evidence-based guidelines, clinical tools and programmatic approaches to strengthen health systems and their ability to provide appropriate care and treatment for the millions of women and girls who have experienced FGM and its consequences, as well as to take actions to prevent the practice. Despite this, key stakeholders (particularly donors) are looking for evidence that their investments will yield expected outcomes to prevent FGM and the associated short- and long-term consequences.

BACKGROUND

Female genital mutilation (FGM) involves the partial or total removal of external female genitalia or other injury to female genital organs for non-medical reasons. It is usually practised on young girls without consent and is estimated to affect 200 million women and girls alive today. The practice of FGM is highly concentrated in many African countries and beyond.
Due to population growth, accelerated efforts to stop the practice are needed or the absolute number of affected girls will rise, along with the health burden and health-related costs. In December 2012 the United Nations General Assembly resolution “Intensifying global efforts for the elimination of female genital mutilations” demonstrated the increased commitment of countries to end this harmful practice. Efforts are urgently needed to prevent the practice of FGM, as articulated in the Sustainable Development Goals (Target 5.3), as well as to improve the capacity of health systems to respond to FGM and provide appropriate care and treatment. Abandoning FGM both locally and nationally is needed to promote human rights for individuals living in areas where the practice is currently prevalent.

The primary sources of nationally representative prevalence data on FGM are household surveys. Economic impact data, however, are lacking. A 2010 study estimated the obstetric costs of FGM as a percentage of overall government spending across six African countries. The total economic burden of FGM was reported to be $3.7 million international dollars across the six countries, and up to 1% of government health spending on women of reproductive age. A 2016 study in the UK showed psychological problems and long-term complications of FGM accrued the largest costs, estimated at an annual £100 million. Exploring the potential cost savings to health systems which could be expected by implementing interventions to prevent FGM and improve management of its complications is a much needed exercise.

This study estimates the economic burden of FGM and the potential benefits of fully or partially abandoning the practice in 27 high-burden countries. This is achieved by determining the incremental risk of health complications in affected girls and women attributable to FGM; determining the costs of healthcare interventions for managing these complications; and estimating the avoidable cost from fully or partially abandoning the practice of FGM.

**METHODS**

**Countries**

The analysis included 27 countries, selected on account of having a high burden of FGM and having information on prevalence by type of FGM available. The included countries were: Benin, Burkina Faso, Central African Republic, Côte d’Ivoire, Cameroon, Chad, Djibouti, Egypt, Eritrea, Ethiopia, Ghana, Guinea, Gambia, Guinea-Bissau, Iraq, Kenya, Mali, Mauritania, Niger, Nigeria, Sudan, Senegal, Sierra Leone, Somalia, Togo, United Republic of Tanzania and Yemen. The adult prevalence of FGM and sources of this data are reported in online supplemental appendix 1.

**Model structure**

A dynamic Markov state-transition model with a time horizon of 30 years was constructed. The model states took into account the different life stages in which health complications from FGM may arise (childhood, reproductive age, periods of pregnancy and childbirth, and later life), and were broadly partitioned into individuals unaffected by FGM, individuals affected by type I/II FGM and individuals affected by type III FGM. This stratification of the population by type of FGM allows estimation of costs specific to FGM typology. The model was run separately for each country of the analysis, using national population age structures. States of the model are shown in online supplemental appendix A. The model was implemented in R v 3.6.1 using the HEEMOD package. The model code and underlying functions were extensively unit tested using RUnit.

**Model parameters and population structure**

Probabilities of transitioning between states were derived from a systematic review and meta-analysis of the clinical and epidemiological literature (see table 1) and public databases. Briefly, model population size and age structure were determined by country from the World Population Prospects (WPP) medium variant revision, using the breakdown by 5-year age groups. Ageing within the model cohort over the 30-year time horizon was represented by dynamically changing transition probabilities between the 0–14, 15–49 and 50+ age groups according to the current population age structure. The model population was initiated according to the baseline national age structure and prevalence of FGM in each country. Specifically, the number currently at risk of FGM was the baseline 0–14-year age group minus those already exposed to FGM, while the adult and later life population with FGM was the FGM prevalence multiplied by the 15–49 and 50+ year population size.

For each country, the General Fertility Rate (GFR, total number of live births per 1000 women aged 15–49) was taken from the medium variant revision 2017 of the WPP for the years 2018–2047. GFR was used to determine the annual probability of a childbirth occurring in the cohort of women of reproductive age (15–49 years). The inflow of population to the model was determined by births of the WPP medium variant revision 2017 extrapolation for each year, using a secondary sex ratio (rate at birth) of 0.489 (105 males to 100 females) to determine annual female births. Further details of model parameters are provided in online supplemental appendix A, while details of model transitions are provided in online supplemental appendix B.

**Annual risk of FGM**

The annual risk of being subjected to FGM was estimated from the prevalence of FGM in the adult population by country, recorded in Demographic and Health Survey (DHS) or Multiple Indicator Cluster Survey (MICS) data. The data from these surveys is categorised as ‘cut, flesh removed’ or ‘sewn closed’, corresponding to type I/II and type III FGM, respectively. It is a limitation of the data that we cannot fully align the categories from population-based studies with the categorisations measuring health complications, but every
Table 1  Health consequences associated with female genital mutilation (FGM), their excess annual risks in FGM-affected individuals and associated economic cost

| Complication                        | Costs and resource utilisation | Annual excess risks in FGM group* | One-time cost† | Applicable FGM types | References |
|-------------------------------------|---------------------------------|----------------------------------|----------------|----------------------|------------|
|                                     | Commodity cost (2018) US$ | Outpatient consultations | Inpatient days | Childhood | Adult: non-reproductive | Adult: reproductive | Later life |     |                               |           |
| Acute consequences                  |                                 |                                 |                |          |                       |                   |           |     |                               |           |
| Abscess on vulvar area              | –                               | 1                               | 1              | 1.3%     | 0.0%                   | 0.0%               | 0.0%       | 1   | III                            | 95         |
| Excessive bleeding                  | –                               | 0                               | 3              | 30.1%    | 0.0%                   | 0.0%               | 0.0%       | 1   | III                            | 2938456694 |
| Excessive bleeding                  | –                               | 0                               | 3              | 18.6%    | 0.0%                   | 0.0%               | 0.0%       | 1   | I/II                           | 7894       |
| Infected wounds                     | –                               | 1                               | 0              | 11.6%    | 0.0%                   | 0.0%               | 0.0%       | 1   | I/II                           | 397894     |
| Infected wounds                     | –                               | 1                               | 0              | 5.2%     | 0.0%                   | 0.0%               | 0.0%       | 1   | III                            | 3994       |
| Genital ulcer                       | –                               | 1                               | 0              | 1.6%     | 0.0%                   | 0.0%               | 0.0%       | 1   | I/II/III                       | 88         |
| Urogenital complications            |                                 |                                 |                |          |                       |                   |           |     |                               |           |
| Bacterial vaginosis                 | 0.29                            | 0.5                             | 0.5            | 0.0%     | 11.4%                  | 0.0%               | 0.0%       | 0   | I/II/III                       | 63         |
| Clitoral neumra                     | –                               | 0                               | 1              | 0.0%     | 0.2%                   | 0.2%               | 0.0%       | 0   | I/II                           | 62         |
| Genitourinary tract (infection)     | 0.29                            | 0.5                             | 0.5            | 0.0%     | 0.6%                   | 0.6%               | 0.0%       | 0   | I/II/III                       | 21         |
| Keloids of labia                   | –                               | 0                               | 1              | 0.0%     | 0.6%                   | 0.6%               | 0.0%       | 0   | I/II                           | 62         |
| Menstrual difficulties              | –                               | 2                               | 0              | 0.0%     | 2.4%                   | 0.0%               | 0.0%       | 0   | I/II/III                       | 46487296   |
| Recurrent UTIs                      | 0.29                            | 0.5                             | 0.5            | 1.9%     | 1.9%                   | 1.9%               | 1.9%       | 0   | I/II/III                       | 63         |
| Kidney infection                    | 0.29                            | 0.5                             | 0.5            | 1.5%     | 1.5%                   | 1.5%               | 1.5%       | 0   | I/II/III                       | 40         |
| Obstetric complications             |                                 |                                 |                |          |                       |                   |           |     |                               |           |
| Caesarean                           | 17.63                           | 0                               | 7              | 0.0%     | 0.0%                   | 4.2%               | 0.0%       | 0   | I/II/III                       | 212732364044454852548487929899 |
| Dystocy                             | 2.71                            | 0                               | 1              | 0.0%     | 0.0%                   | 9.0%               | 0.0%       | 0   | I/II/III                       | 406379     |
| Episiotomy                          | 0.07                            | 0                               | 0              | 0.0%     | 0.0%                   | 25.4%              | 0.0%       | 0   | I/II                           | 516293101  |
| Episiotomy                          | 0.07                            | 0                               | 0              | 0.0%     | 0.0%                   | 38.5%              | 0.0%       | 0   | III                            | 22101102   |
| Low birth weight                    | –                               | 0                               | 0              | 0.0%     | 0.0%                   | 2.0%               | 0.0%       | 0   | I/II/III                       | 2280102    |
| Obstructed labour                   | 2.71                            | 0                               | 1              | 0.0%     | 0.0%                   | 4.0%               | 0.0%       | 0   | I/II/III                       | 407298     |
| Perineal tear (second degree)       | 0.07                            | 0                               | 0              | 0.0%     | 0.0%                   | 12.3%              | 0.0%       | 0   | I/II                           | 93         |
| Perineal tear (third degree)        | 0.07                            | 0                               | 0              | 0.0%     | 0.0%                   | 5.3%               | 0.0%       | 0   | I/II                           | 93         |
| Perineal tear (first degree)        | 0.07                            | 0                               | 0              | 0.0%     | 0.0%                   | 10.7%              | 0.0%       | 0   | I/II                           | 93         |
| Perineal tear (third degree)        | 0.07                            | 0                               | 0              | 0.0%     | 0.0%                   | 10.0%              | 0.0%       | 0   | III                            | 99         |

Continued
Table 1  Continued

| Complication                 | Commodity cost (2018) US$ | Outpatient consultations | Inpatient days | Annual excess risks in FGM group* | One-time cost† | Applicable FGM types | References |
|------------------------------|---------------------------|--------------------------|----------------|-----------------------------------|----------------|----------------------|------------|
| Urethral tear                | 0.07                       | 0                        | 0              | 0.0% 0.0% 3.5% 0.0%               | 0              | III                  | 45         |
| Urethral tear                | 0.07                       | 0                        | 0              | 0.0% 0.0% 4.3% 0.0%               | 0              | I/II                 | 93         |
| Newborn resuscitated         | 0.49                       | 0                        | 2              | 0.0% 0.0% 4.4% 0.0%               | 0              | I/II/III             | 40 84      |
| Psychological/sexual complications |                           |                          |                |                                   |                |                      |            |
| Anxiety (moderate to severe) | 3.93                       | 2                        | 0.28           | 0.0% 4.1% 0.0% 4.1%               | 0              | I/II/III             | 28         |
| Depression (moderate to severe) | 3.93                      | 2                        | 0.28           | 0.0% 1.3% 0.0% 1.3%               | 0              | I/II/III             | 67         |
| Dyspareunia                  | –                          | 1                        | 0              | 0.0% 2.8% 0.0% 0.0%               | 0              | I/II/III             | 19 21 46 48|
| Sexual dysfunction           | –                          | 1                        | 0              | 0.0% 3.2% 0.0% 0.0%               | 0              | I/II/III             | 91         |

*Excess risk is the additional annual risk of each complication in an FGM-affected individual.
†1 if the cost is associated with the acute FGM event, 0 otherwise.
FGM; and school-based and health sector-based education initiatives. However, most studies explored the effects of interventions on intermediate outcomes, not on actual reductions in the practice of FGM. Further, most of the interventions were evaluated using pre- and post-test designs or quasi-experimental study designs, and did not have sufficient statistical power to detect changes in outcomes.

Given the limitations in study designs and lack of replication in a range of settings, we did not model incidence reductions as a result of specific interventions in the 27 study countries. Rather, this analysis opted for a continuation of the most recently observed incidence and two hypothetical change scenarios with partial and complete reduction in the incidence of FGM, the latter being an admittedly optimistic scenario but one contemplated in the Sustainable Development Goals. The authors further recognise that FGM prevalence is declining in some countries, while in others it is stable, and in yet others it is increasing. The assumption of continuation of current incidence in the absence of intervention is therefore debatable as it masks country level variation; however, given the variability in these trends and the unpredictability of their trajectory, the current incidence scenario provides a reference scenario against which to compare the projected declines reflected in the hypothetical intervention scenarios.

These hypothetical interventions were assumed to have an effectiveness of 50% (partial abandonment) and 100% (full abandonment) in the reduction of the annual risk of FGM for girls aged 0–14. The effect of interventions was assumed to be immediate from the first model year. Due to the irreversible nature of FGM, abandonment of FGM does not eliminate the prevalent population. Consequently, in our model abandonment only affects the number of FGM-affected individuals in the 0–14-year age groups. Abandonment was assumed to reduce the risk of FGM equally among all girls aged 0–14.

**Resource utilisation**

Healthcare utilisation associated with FGM was based on a review and meta-analysis of the literature on clinical complications associated with FGM. All complications for which a significant association with FGM was found, and for which corresponding interventions could be identified, were included in the healthcare utilisation calculations. Random effects meta-analyses were used to estimate the pooled (inverse variance) absolute difference in risk between FGM and non-FGM groups using STATA 16. The economic burden associated with FGM was calculated by linking each clinical complication with a clinical management strategy, sourced from the WHO OneHealth tool list of interventions, the scientific literature and expert opinion (table 1). As outlined in table 1, costs associated with specific health complications were assigned to either prevalent type I/II, type III or any FGM (type I/II/III) cases, depending on the associations supported by the literature review.

Country-specific healthcare utilisation rates for specific health complications were not included in the model as these data were not available. Some existing research suggests that women’s FGM status can also impact her healthcare utilisation, making her less likely to seek treatment. However, since most of the data on health risk are based on facility-based studies of women seeking care for some health services (most often maternal or reproductive health services), these studies suggest that women with FGM do seek care for health services and do receive treatments for FGM-related complications even if the proportion of women receiving treatment for particular health complications is not available. The healthcare costs calculated in this study constitute the costs of treating health conditions that may arise from FGM. These costs will be an overestimate of the actual healthcare costs of women seeking care for these conditions since many women will not seek care and health systems in the study countries may not currently routinely diagnose or offer care for these services.

**Unit costs**

Unit costs were derived from the WHO OneHealth tool appendix on Intervention Assumptions, which describes human resources, medicines, consumables and other resources required for individual clinical interventions. Details of these interventions and unit costing are given in online supplemental appendix E. When no information was available in the OneHealth tool for specific complications (genital wounds and ulcers, clitoral neuroma, keloids of labia, post-traumatic stress syndrome), a targeted literature review was carried out to identify published evidence of unit costs (online supplemental appendix F); however, no appropriate unit costs were identified. In such cases, unit costs were based on expert opinion in combination with sources describing the clinical management of these complications. Global unit costs were used for commodities, while country-specific unit costs from WHO-CHOICE were used for costs of outpatient consultations and inpatient bed days. As no country costs were available for Somalia, values from the Central African Republic were used as a proxy.

Unit costs were inflated from base year US$ (2010 for inpatient and outpatient consultation costs; 2015 for commodity costs sourced from OneHealth Tool) to 2018 US$ using country-specific GDP deflators.

All global unit costs are summarised together with relevant clinical complications in table 1. Country-specific costs of outpatient consultations and inpatient days are included in online supplemental appendix J.

For reporting, costs are stratified by acute complications (bleeding, abscesses, etc), uro-gynaecological complications (urinary tract infections, neuruma, etc), obstetric and neonatal complications (caesarean sections, dystocia, etc) and psychological/sexual complications (anxiety, depression, etc), as outlined in table 1.
Sensitivity analysis

We undertook one-way deterministic sensitivity analyses using plausible ranges for the parameters anticipated to have a substantial impact on the model results, including annual incidence of different types of FGM, background mortality rates, annual births, and sub-categories of costs: acute complications, infections, scarring and obstetrics (detailed in online supplemental appendix G). Due to lack of data on distribution or plausible ranges of these parameters, we varied point estimates from 0.5× to 2× the base case value, except for cost categories where we varied point estimates from 0.25× to 4× the base case value. Cost sub-categories were examined in sensitivity analysis in aggregate rather than individual risks and unit costs, due to the many constituent parts of these sub-categories. A total of 27 model parameters were examined, and sensitivity analysis was undertaken at the country level to account for differences in context and country-specific consultation costs. An overview of the parameters varied in the sensitivity analysis and the range is given in online supplemental appendix G.

RESULTS

Multiple health consequences are associated with FGM. A systematic review and meta-analysis undertaken by WHO has linked FGM with multiple health complications across the life course. An overview of the complications included in this study is given in table 1.109 The complications are broadly categorised as acute complications arising directly from FGM, uro-gynaecological complications arising directly in the affected tissue and the broader urogenital system, obstetric complications, and psychological and sexual complications (based on literature identified according to Robbers et al).109

FGM typically occurs in the childhood years and affects individuals across the life course. Figure 1 shows the evolution of adult prevalence of FGM over 30 years for the included countries. To assess the potential impact of reduction in FGM through initiatives to prevent the practice, our model suggests the effect of preventing FGM by 50% during childhood would reduce the adult prevalence of FGM by a median of 24% (IQR 22–26%) across countries over 30 years. Full abandonment of FGM would result in a median reduction in adult prevalence of 55% (IQR 52–57%) across countries over 30 years.

In the model, the total economic burden of FGM is a function of both prevalence and population size. Figure 2 outlines the total projected population growth in the 27 countries, along with the projected prevalent cases of FGM in our model. The number of prevalent FGM cases in the current incidence scenario, in which no reductions in FGM occur, follows the same trend as the general population growth, substantially increasing over time from 119.4 million cases at baseline to 205.8 million in 2047 (note that our model does not include all countries for which the global estimate of 200 million cases cited in the literature is derived). A partial abandonment of FGM by 50% is not sufficient to cause a reduction in prevalent cases over the model time horizon, which in this case results in a total of 154.5 million prevalent cases by 2047. In contrast, full abandonment of FGM does result in a reduction in total prevalent cases from 119.4 million at baseline to 80.0 million in the year 2047.

Each prevalent case of FGM is associated with increased healthcare utilisation. The projected economic burden of FGM across countries is shown in figure 3. Due to increasing prevalent cases, the annual economic burden in a current incidence scenario is projected to increase steadily over the time horizon, rising from approximately US$1.4 billion in 2018 to over US$2.1 billion per year in 2047. A partial abandonment by 50% results in a slower increase towards US$1.7 billion per year in 2047. Full elimination of FGM would cause a gradual reduction in the annual economic burden from US$1.4 billion in 2018 to US$0.8 billion in 2047. Figure 3 also shows the majority of the economic burden is in adults who are not...
currently pregnant or giving birth. The prevalent cases and total economic burden per year suggest a burden of US$10.37–12.46 per prevalent case per year across countries (data not shown). The economic burden per prevalent case depends on a mix of factors including country-specific human resource costs, relative prevalence of FGM types, remaining life expectancy of the FGM affected cohorts, and the relative contribution of new FGM cases (acute complications) versus life-time complications (prevalent cohort).

Costs are incurred across the life course, starting with the acute complications of FGM. Long-term consequences continue into adulthood and during the reproductive cycle, and during the later years of life. The relative contribution to the total economic burden of the four categories of complications examined here is shown in figure 4 for the current incidence scenario over the 30-year time horizon. As also seen in figure 3, the majority of the burden in the current incidence scenario is among adults of reproductive age, within which urogynaecological complications account for the largest burden, followed by psychological/sexual complications. Women who are pregnant and giving birth account for the second largest share of the total economic burden.

The sensitivity analysis by country showed the model was generally sensitive to the annual risk of different types of FGM. This is expected, as the annual risk determines how many new individuals with FGM are present in the population in addition to the prevalent FGM population. Across countries, a 50% reduction in incidence translated into a decrease of approximately 20% in total cost. The model was also generally sensitive to cost categories. In the most substantial cases, a 75% reduction in the cost category estimate was associated with a reduction.
DISCUSSION

The evidence on the economic burden of FGM is scarce and previous estimates have focused on obstetric costs. This study provides the first estimates of costs associated with treating a wider range of health conditions associated with FGM, identified through meta-analyses of data from scientific studies comparing women with and without FGM, by types. Costs have been calculated by year over a 30-year period (2017 to 2047) by applying health risk estimates by type of FGM to FGM prevalence data by type and population data, and assigning cost values to treating these health conditions from existing data sources.

In our projections we find that even a partial abandonment of FGM by 50% does very little to curb the rise in the economic burden of FGM. Substantial population growth over the next 30 years means the number of cases will continue to rise unless full abandonment is achieved.

However, as a substantial proportion of the economic burden of FGM is concentrated in adults of reproductive age, the economic burden of FGM will continue to be substantial over the next 30 years even if new cases can be prevented.

We find that the economic burden of FGM is currently approximately US$1.4 billion per year. Without action, this cost would increase to US$2.1 billion per year by 2047 due to the increase in prevalent cases with population growth. In contrast, full abandonment of FGM would lead to a gradual reduction in economic burden, down to approximately US$800 million per year in 2047. In these estimates we assume a continuation of current incidence in the absence of interventions as a reference scenario. By extension, if FGM trends were systematically declining in all countries without further intervention, our estimate of US$2.1 billion by 2047 in the current incidence scenario would be an upper bound. However, as we have shown a reduction of 50% in incidence is not sufficient to reduce total cases by 2047, any such secular
trends in FGM practices are not likely to meaningfully impact the burden in the medium to long term.

The actual health expenditures of treating FGM and the health utilisation data for treatment of the included health complications are not known. Therefore, the results of this analysis show the estimated costs associated with treating the health burden of FGM. Countries’ health financing is likewise not taken into account; health expenditures to treat these complications could potentially include public or private sources as well as out-of-pocket payments.

Recently, estimates have been produced on the costs and impacts of scaling up interventions against FGM. These estimates suggest a total cost of interventions of US$3.3 billion from 2020 to 2030 across 31 high burden countries, including prevention through community engagement, mass media and healthcare provider engagement, protection through legislative efforts, treatment of the psychosocial consequences and capacity building among healthcare providers. This coverage is estimated to avert 4.6 million cases of FGM between 2020 and 2030, and an additional 19.8 million cases during 2031–2050.

In our work, based on population growth and even a 50% reduction in the practice of FGM, we estimate that around 50 million total prevalent cases could be avoided by 2047, with a reduction in the annual burden of US$400 million per year by 2047. This does not factor in gains in quality of life, economic productivity or other aspects of FGM that can be valued. Although results from these studies cannot be directly compared, these estimates suggest a favourable cost-effectiveness of interventions seeking to end FGM. However, while our analysis suggests a burden of approximately US$10–12 per prevalent case of FGM, the cost-effectiveness of interventions in some settings is estimated to be higher at around US$240 per case averted. These observations highlight the importance of identifying interventions that are tailored to specific settings for maximum effectiveness.

There are multiple innovative and promising approaches being implemented in high prevalence countries, and evaluations have shown evidence on changes in intermediate outcomes such as changes in attitudes and reduced support for FGM; improved knowledge about the practice, its harms and its illegality; and intentions to perform FGM. For example, community engagement through information sessions on health, rights and female empowerment, school-based education, and health education within health facilities as well as communications campaigns using social marketing and other communications approaches show promising results on intermediate outcomes such as knowledge, intentions to cut and reduction in attitudes supportive of FGM. In addition, investing in education of girls and women appears to be associated with decreased support for FGM, and women with higher levels of education were less likely to have their daughters undergo FGM. While these are relevant indicators of social norm change and likely precursors to abandonment, more studies are needed to demonstrate the effectiveness of the approaches in terms of reducing FGM practices, and the replicability of these programmes in different settings. For these reasons, the projections presented on reductions in FGM incidence in the present work are not tied to particular interventions but rather to hypothetical reductions which might be achieved based on a set of context-specific programmatic interventions selected for a particular setting.

Limitations
A few limitations of the analysis should be noted. Three countries for which FGM prevalence data were available were not included because data on the breakdown of types of FGM were not available. Two of these countries, Indonesia and Liberia, have a high prevalence of FGM (49% and 44%, respectively), but since different risks are assigned by type of FGM, and since these countries did not have data available by FGM type, they were excluded from the analysis.

The present model uses uniform unit costs of commodities across countries and country-specific unit costs for outpatient consultations and inpatient days. While this is a simplification, we believe the basic commodities required for most of the interventions included here are not subject to large variation in procurement cost and, additionally, the costs of commodities are modest compared with the costs of consultations and inpatient days.

The model makes assumptions around treatment-seeking behaviour. In our work we model the economic impact assuming all healthcare needs result in formal healthcare contact. While we acknowledge that a proportion of healthcare need would result in informal care seeking, or no care seeking at all, we present this analysis in the context of the move towards universal health coverage (UHC). Consequently, our results should be interpreted as the economic burden in a setting with or close to achieving UHC.

We do not model the economic impact of mortality or indirect costs of productivity loss. As such, our model presents only direct costs to the healthcare system associated with FGM and is likely to be an underestimate of the true negative economic and societal impact of FGM.

We recognise that the economic burden will differ between countries, and in particular that our estimates may overestimate costs in settings where rates of FGM are systematically and consistently declining.

Finally, although we include costs related to psychological and sexual health complications, our model does not capture impacts on quality of life or the intangible burden associated with pain, sexual dysfunction or other consequences of FGM. A complementary review of the qualitative literature on FGM and psychosocial well-being discusses these effects.
CONCLUSIONS

Our analysis calculates healthcare costs associated with treating FGM complications but does not consider costs due to loss of productivity, reduced quality of life, mortality and psychosocial complications that might result from FGM and which adversely impact the health and well-being of women and girls who have undergone FGM. As such, this work presents a highly conservative estimate of the total burden of FGM on individuals and society.

Despite these limitations, the analysis provides important arguments for the abandonment of FGM. This traditional harmful practice affects 200 million women and girls alive today and this number will rise without urgent action. The practice violates human rights, causes significant suffering and negative impacts on women’s health in the short and long term, and should be abandoned for these reasons alone. Demonstrating that it also increases economic costs to society and women and that these costs will increase over time is yet another reason to accelerate efforts to abandon this harmful practice. These findings support the urgency to end FGM.

Author affiliations
1WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht, The Netherlands
2Triangulate Health Ltd, Doncaster, UK
3Independent Consultant, London, UK
4University College London, London, UK
5School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
6Institute of Public Health, Pontificia Universidad Javeriana, Bogotá, Colombia
7Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Victoria, Australia
8UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland

Twitter David Tordrup @david_tordrup and Joshua P Vogel @josh_vogel

Contributors CP and DT designed the study, which was conceptualised and initiated by CP. DT built the model with input from CP and NG. DT coordinated incorporation of model parameters from CP, MP and FRV. NG undertook the targeted literature review for model parameters. MP conducted statistical analysis of health burden data on FGM. FRV created and managed the health burden database based on systematic reviews and screening conducted by FRV, JV and CP. CB extracted and synthesised unit costs from the OneHealth Tool. DT, CB and CP drafted the manuscript with input from all other authors. All authors reviewed the manuscript prior to submission. CP is the guarantor of the overall content and provided the final version of the manuscript prior to submission. CP . CB extracted and synthesised unit costs from the OneHealth Tool. DT, CB and NG undertook the incorporation of model parameters from CP, MP and FRV. NG undertook the targeted literature review for model parameters. MP conducted statistical analysis of health burden data on FGM. FRV created and managed the health burden database based on systematic reviews and screening conducted by FRV, JV and CP. CB extracted and synthesised unit costs from the OneHealth Tool. DT, CB and CP drafted the manuscript with input from all other authors. All authors reviewed the manuscript prior to submission. CP is the guarantor of the overall content and provided the final version of the manuscript prior to submission.

Funding This study was conducted with the financial support of the Government of Norway, the Government of the United Kingdom and the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a co-sponsored programme executed by the World Health Organization (WHO).

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data provided as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Author note The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

ORCID iDs
Joshua P Vogel http://orcid.org/0000-0002-3214-7096
Christina Pallitto http://orcid.org/0000-0002-7779-9303

REFERENCES

1 United Nations Children’s Fund (UNICEF). Female genital mutilation, 2021United Nations Children’s Fund (UNICEF). Available: https://data.unicef.org/topic/child-protection/female-genital-mutilation/ [Accessed 16 November 2021].
2 UNICEF. Female Genital Mutilation/Cutting: A statistical overview and exploration of the dynamics of change. New York UNICEF; 2013.
3 World Health Organization. Health risks of female genital mutilation, 2021. Available: https://www.who.int/teams/sexual-and-reproductive-health-and-research/jrh/areas-of-work/female-genital-mutilation/health-risks-of-female-genital-mutilation [Accessed 16 November 2021].
4 World Health Organization. Female genital mutilation: fact sheet. Geneva: WHO; 2020. https://www.who.int/news-room/factsheets/detail/female-genital-mutilation [Accessed 16 November 2021].
5 United Nations Population Fund (UNFPA). Bending the curve: FGM trends we AIM to change. New York: UNFPA; 2018. https://www.unfpa.org/sites/default/files/resource-pdf/18-003_FGM-Infographic-2018-02-05-1804.pdf [Accessed 16 November 2021].
6 Bewley S, Creighton S, Momo C. Female genital mutilation. BMJ 2010;340:c2728.
7 Bishai D, Bonnenta Y-T, Darwish M, et al. Estimating the obstetric costs of female genital mutilation in six African countries. Bull World Health Organ 2010;88:281–8.
8 Hex N, Hanlon J, Wright D. Estimating the costs of female genital mutilation services to the NHS Partnership for Responsive Policy Analysis and Research; 2016. https://www.york.ac.uk/media/healthsciences/images/research/prepare/reportsandtheicrover images/EstimatingCostsOfFGMServices.pdf [Accessed 15 Nov 2021].
9 R Core Team. R: a language and environment for statistical computing, 2019.
10 Filipović-Pierucci A, Zarca K, Durand-Zaleski I. Markov models for health economic evaluation: the R package heemod. ArXiv 2017.
11 Burger M, Juennemann K, Koeng T. RUnit: R unit test framework, 2018.
12 United Nations. World population prospects 2017 revision, 2017. Available: https://population.un.org/wpp/Download/Standard/Population/
13 World Health Organization. Sex ratio. Available: http://origin.searo.who.int/entity/health_situation_trends/data/chi/sx-ratio/en/.
14 Ballot H, Murray N, Connelly E, et al. Addressing female genital mutilation in Europe: a scoping review of approaches to participation, prevention, protection, and provision of services. Int J Equity Health 2018;17:1–15.
15 Berg RC, Denison EM. A realist synthesis of controlled studies to determine the effectiveness of interventions to prevent genital cutting of girls. Paediatr Int Child Health 2013;33:222–3.
16 Johansen REB, Diop NJ, Laverack G. What works and what does not: a discussion of popular approaches for the abandonment of female genital mutilation. Obstet Gynecol Int 2013;2013:1–10.
17 Feldman-Jacobs C. Ending female genital mutilation/cutting: lessons from a decade of progress, 2013. Available: http://www.prb.org/Publications/Reports/2014/progress-ending-fgm.aspx
W aigwa S, Doos L, Bradbury-mutilation/cutting (FGM/C): a systematic review. *Int J Gynecol Obstet* 2016;132:305–8.

Abdulcadir J, Botsikas D, Bolmont M, et al. Sexual anatomy and function in women with and without genital mutilation: a cross-sectional study. *J Sex Med* 2016;13:226–37.

Andro A, Cambios E, Lessingland M. Long-term consequences of female genital mutilation in a European context: self-perceived health of FGM women compared to non-FGM women. *Soc Sci Med* 2014;106:177–84.

Ankilew CC, Ekereme BN, Obiechina NJ, et al. Female genital mutilation and obstetric outcome: a cross-sectional comparative study in a tertiary hospital in Abakaliki South East Nigeria. *Eur J Obstet Gynecol Reprod Biol* 2019;1:100005.

Anis TH, Aboul Gheit S, Alwagih M, et al. Term consequences of female genital mutilation on birth outcomes in Jigjiga town, Ethiopian Somali region: a prospective cohort study. *BMC Pregnancy Childbirth* 2018;18:305.

Akinosile-Smith AM. Exploring female genital cutting among West African immigrants. *J Immigr Minor Health* 2014;16:559–61.

Agu W, Abdulahi M. Labor, delivery and postpartum complications in nulliparous women with female genital mutilation admitted to KARAMARA Hospital. *Ejorph Med J* 2017;35:11–17.

Direction Nationale de la Statistique (DMS) et ORC Macro. *Enquête Démographique et de Santé, Guinée* 1999. Calverton, Maryland, USA: Direction Nationale de la Statistique et Macro International Inc, 2000.

Direction Nationale de la Statistique (DMS) et ORC Macro. *Enquête Démographique et de Santé, Guinée* 2005. Calverton, Maryland, USA: DNS et ORC Macro, 2006.

Hasim LY. Impact of female genital mutilation on maternal and neonatal outcomes during parturition. *East Afr Med J* 2001;78:255–8.

Holmgren B, da Silva Z, Larsen O, et al. Dual infections with HIV-1, HSV-2 and HTLV-1 and HTLV-2 among common in older women than in men in Guinea-Bissau. *AIDS* 2003;17:241–53.

Ibrahim ZM, Ahmed MR, Sayed Ahmed WA. Prevalence and risk factors for female sexual dysfunction among Egyptian women. *Arch Gynecol Obstet* 2015;292:613–80.

Ismail SA, Abbas AM, Habib D, et al. Effect of female genital mutilation/cutting: types I and II on sexual function: case-controlled study. *Reprod Health* 2017;14:108.

Kanki P, M’Boup S, Martink R, et al. Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in West African female prostitutes. *Am J Epidemiol* 1992;136:895–907.

Kaplan A, Forbes M, Bonhoure I, et al. Female genital mutilation/ cutting in the Gambia: long-term health consequences and complications during delivery and for the newborn. *Int J Womens Health* 2013;5:323–31.

Kasim K, Shaaban S. Impacts of female genital mutilation on complications during delivery and for the newbor. *Int J Womens Health* 2012;4:279–82.

Khodabakhshi Koolaee A, Pourrebrahim T, Mohammadmoradi B, et al. The comparison of marital satisfaction and mental health in Oriental mutilated females and non-genital mutilated females. *Int J High Risk Behav Addict* 2012;1:115–20.

Kozlowski A, de-Leuscher M, Elbert T. Psychopsychoedical sequelae of female genital mutilation and their neuroendocrinological associations. *BMJ Global Health* 2018;3:187.
BMJ Global Health

68 Larsen U, Okonofua FE. Female circumcision and obstetric complications. *Int J Gynaecol Obstet* 2002;77:255–65.

69 Larsen U, Yan S. Does female circumcision affect infertility and fertility? A study of the central African Republic, Côte d’Ivoire, and Tanzania. *Demography* 2000;37:313–21.

70 Larsen U. The effects of type of female circumcision on infertility and fertility in Sudan. *J Biosoc Sci* 2002;34:363–77.

71 Maheu-Giroux M, Filippi V, Maulet N, et al. Risk factors for vaginal fistula symptoms in Sub-Saharan Africa: a pooled analysis of national household survey data. *BMC Prev Child* 2016;16:32.

72 Mahmoud MIH. Effect of female genital mutilation on female sexual function, Alexandria, Egypt. *Alexandria J Med* 2016;52:55–9.

73 Mahmoudi O, Hosseini E. Psychosocial complications of female genital mutilation for couples: a comparative study. *J Kermanshah Univ Med Sci* 2017;10:125–40.

74 Cellule de Planification et de Statistique du Ministère de la Santé (CPS/MS), Direction Nationale de la Statistique et de l’Informatique (DINS) et ORC Macro. Enquête Démographique et de Santé Au Mali. Calverton, Maryland, USA: CPS/MS, DINSI et ORC Macro; 2002. https://www.dhsprogram.com/pubs/pdf/FR134/FR134-ML01.pdf [Accessed 16 November 2021].

75 Almothe L, Elmusharaf S, El Hadi N, et al. Primary infertility after female genital mutilation in girdhoo in Sudan: a case-control study. *Lancet* 2005;366:385–91.

76 Cellule de Planification et de Statistique du Ministère de la Santé (CPS/MS), D. N. de la, Statistique et de l’Informatique du Ministère de l’Économie, de l’Industrie et du C. & 2007., (DNSI/MEIC) et Macro International Inc. Enquête Démographique et de Santé Du Malì 2006. Calverton, Maryland, USA: CPS/DNSI et Macro International Inc. 2006.

77 Maslosavskya O, Brown JJ, Padmasas SS. Disentangling the complex association between female genital cutting and HIV among Kenyan women. *J Biosoc Sci* 2009;41:815–30.

78 Office National de la Statistique (ONS) [Mauritani] et ORC Macro. Enquête Démographique et de Santé (EDS) beauté. Casablanca 2000-2001. Calverton, Maryland, USA: ONS et ORC Macro, 2000.

79 Millogo-Traore F, Kabia STA, Thieba B, et al. Pronostic maternal et fatai au cours de l’accouchement chez la femme excisiée. *J Gynecol Obstet Biol Reprod* 2007;36:393–3.

80 Minsart A-N, Faye A-T-S, Ali Hadji D, et al. Maternal infibulation and obstetrical outcome in Djibouti. *J Matern Neonatal Med* 2007;20:135–40.

81 Mohammed GF, Kaba STA, Thieba B, et al. Primary infertility after female genital mutilation. *Int J Gynaecol Obstet* 2017;139:21–7.

82 Mingnao F, Kaba STA, Thieba B, et al. Effects of type of female circumcision on infertility and fertility. *Fertil Steril* 2010;93:643–53.

83 Musy M, Bazaar M, Askia M, et al. Female genital cutting in Kilimanjaro, Tanzania: changing attitudes? *Trop Med Int Health* 2002;7:158–65.

84 Ndiaye S, A yad M. Impact of female genital mutilation on female sexual function and obstetrical outcome in Djibouti. *J Mamm Neonat Med* 2010;23:72–4.

85 Ndayi P. Matilisation génitale féminine et complications de l’accouchement dans la province de Gourma (Burkina Faso). *Sante Publique* 2010;22:563–70.

86 Oddo A, Brody SP, Elkins TE. Female genital mutilation in rural Ghana. West Afr J Med 2009;28:171–6.

87 Odusina OA, Harriun RA, et al. The effectiveness of female genital mutilation and its effect on delivery outcomes in the Kassena-Nankana district of northern Ghana. *Ghana Med J* 2006;40:87–92.

88 Okonofua FE, Larsen U, Orsonaye F, et al. The association between female genital cutting and correlates of sexual and gynaecological morbidity in Edo state, Nigeria. *BJOG* 2002;109:1089–96.

89 Ofori-JJ. Female genital mutilation (FGM) and sexual functioning of married women in Ovorornokoh Community, Lagos State, *Nigeria. Etude la Popul Africaine* 2015;29:1526–40.

90 Peipin J, Plamondon M, Alves AC, et al. Parenteral transmission associated factors among students of Bahir Dar University, Amhara Regional National State, Ethiopia: a cross-sectional study. *Pan Afr Med J* 2014;17:246.

91 Amin MM, Rasheed S, Salem E. Lower urinary tract symptoms following female genital mutilation. *Int J Gynaecol Obstet* 2013;123:7–13.

92 Slaughter TE, Snow RC, Okonofua FE. The impact of female genital cutting on first delivery in Southwest Nigeria. *Stud Fam Plann* 2002;33:173–84.

93 Thierry A, Kindu A, Toure M, et al. Complications obstétricales des mutilations génitales en milieu rural Malien. *J Gynécologie Obs Biol Reprod* 2015;44:276–9.

94 Ahmed UT, Ismail S, Kunna A. Impact of female genital mutilation on second stage of labour in primigravida at Omdurman maternity Hospital, Sudan 2010. *Sudan Journal of Medical Sciences* 2010;20:1284–9.

95 Varol N, Dawson A, Turkmani S, et al. Obstetric outcomes for women with female genital mutilation at an Australian hospital, 2006–2012: a descriptive study. *BMC Prev Child* 2016;16:1–11.

96 WHO study group on female genital mutilation and obstetric outcome, Banks E, Meink O, et al. Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. *Lancet* 2006;367:1835–41.

97 West S, Rao I, Wyssmueller D, et al. Effects of female genital mutilation on birth outcomes in Switzerland. *BJOG* 2009;116:1204–9.

98 Yassin K, Idris HA, Ali AA, Characteristics of female sexual dysfunctions and obstetric complications related to female genital mutilation in Omdurman maternity hospital, Sudan. *Reprod Health* 2018;15:7.

99 CSO and MI. Yemen demographic and maternal and child survey 1997. Calverton, Maryland, USA: CSO and MI, 1998.

100 Yount KM, Abraham BK. Female genital cutting and HIV/AIDS among Kenyan women. *Stud Fam Plann* 2007;38:73–88.

101 Zayed AA, Ali AA. Abusing female children by circumcision is continued in Egypt. *J Forensic Leg Med* 2012;19:196–200.

102 Andersson SHA, Rymer J, Joyce DW, et al. Sexual quality of life in women who have undergone female genital cutting: a case-control study. *BJOG* 2012;119:1606–11.

103 Robbers G, Vogel JP, Vallejo FR, et al. The health consequences of female genital mutilation: protocol for a systematic review and meta-analysis. *PROSPERO CRD42020164693*, 2020. Available: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020164693

104 Avenir. OneHealth intervention input manual. OneHealth tool, 2016. Available: http://avenerhealth.org/Download/Spectrum-Manuals/Treatment Assumptions 2016 1 10.pdf

105 Kimani S, Kabiru CW, Muteshi J, et al. Exploring barriers to seeking health care among Kenyan Somali women with female genital mutilation: a qualitative study. *BMJ Int Health Hum Rights* 2020;2:3.

106 WHO-CHOICE. WHO Health service delivery costs. Available: https://www.who.int/choice/cost-effectiveness/inputs/health_service/en/

107 The World Bank. Inflation, GDP deflator: linked series (annual %) Available: https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG

108 Kat I, Sanders R, Carvalho MN, et al. Cost and impact of scaling up female genital mutilation prevention and care programs: estimated resource requirements and impact on incidence and prevalence. *PLoS One* 2016;11:e015012.

109 Diop NJ, Askew I. The effectiveness of a community-based education program on abandoning female genital mutilation/cutting in Senegal. *Stud Fam Plann* 2009;40:307–18.

110 UNICEF. Long-term evaluation of the Tostan programme in Senegal: Koulikoro, Thies and Fatack regions. *Stat Morit Sect* 2008.

111 Ausken-Olarinmoye EO, Amusan OA. The impact of health education on attitudes towards female genital mutilation (FGM) in a rural Nigerian community. *Eur J Contracept Reprod Health Care* 2008;13:289–97.

112 Mahgoub E, Nimir M, Abdalla S, et al. Effects of school-based health education on attitudes of female students towards female genital mutilation in Sudan. *East Mediterr Health J* 2019;25:406–12.

113 94
119 Ekwueme OC, Ezegwui HU, Ezeoke U. Dispelling the myths and beliefs toward female genital cutting of woman: assessing general outpatient services at a tertiary health institution in Enugu state, Nigeria. *East Afr J Public Health* 2010;7:64–7.

120 UNICEF. The dynamics of social change towards the abandonment of female genital mutilation/cutting in five African countries. *Innocenti Insight* 2010.

121 Suzuki C, Meekers D. Determinants of support for female genital cutting among ever-married women in Egypt. *Glob Public Health* 2008;3:383–98.

122 Evans WD, Donahue C, Snider J, et al. The Saleema initiative in Sudan to abandon female genital mutilation: outcomes and dose response effects. *PLoS One* 2019;14:e0213380.

123 Hussein SA, Ghattass S. ‘No to circumcision’: the road to effective social marketing campaigns in Egypt. New York Population Council. Evidence to End FGM/C: Research to Help Girls and Women Thrive; 2019. https://knowledgecommons.popcouncil.org/departments_sbsr-rh/1011/

124 Barsoum G, Rifaat N, El-Gibaly O. Poverty, Gender, and Youth Working Paper no. 22. National efforts toward FGM-free villages in Egypt: the evidence of impact. New York Population Council; 2011. https://knowledgecommons.popcouncil.org/departments_sbsr-pgy/152/

125 Rawat R. The association between economic development, education and FGM in six selected African countries. *Afr J Midwifery Womens Health* 2017;11:137–46.

126 Ameyaw EK, Tetteh JK, Armah-Ansah EK, et al. Female genital mutilation/cutting in Sierra Leone: are educated women intending to circumcise their daughters? *BMC Int Health Hum Rights* 2020;20:19.

127 Afifi M. Women’s empowerment and the intention to continue the practice of female genital cutting in Egypt. *Arch Iran Med* 2009;12:154–60.

128 O’Neill S, Pallitto C. The consequences of female genital mutilation on psycho-social well-being: a systematic review of qualitative research. *Qual Health Res* 2021;31:1738–50.